Latest Period
Q4 2025
Security Snapshot
ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) Institutional Ownership
CUSIP: 02043Q107
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
839
Shares (Excl. Options)
129,412,755
Price
$397.65
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- ALNY on Nasdaq
- Shares outstanding
- 132,795,065
- Price per share
- $333.00
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 129,412,755
- Total reported value
- $51,476,964,087
- % of total 13F portfolios
- 0.01%
- Share change
- -1,012,226
- Value change
- -$544,089,414
- Number of holders
- 839
- Price from insider filings
- $333.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 02043Q107.
- 839 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 839 to 237 between Q4 2025 and Q1 2026.
- Reported value moved from $51,476,964,087 to $1,185,680,288.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 839 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 02043Q107?
CUSIP 02043Q107 identifies ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 02043Q107:
Significant Owners of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 13% | $7,676,347,201 | 16,834,095 | FMR LLC | 30 Sep 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.4% | $2,350,677,826 | 7,104,536 | Vanguard Capital Management | 31 Mar 2026 | |||
| Capital Research Global Investors | 5.4% | $1,690,630,939 | 6,968,513 | Capital Research Global Investors | 31 Dec 2024 |
As of 31 Dec 2025, 839 institutional investors reported holding 129,412,755 shares of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY). This represents 97% of the company’s total 132,795,065 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Capital World Investors | 12% | 16,301,772 | -0.81% | 0.88% | $6,482,389,029 |
| FMR LLC | 12% | 15,902,149 | -5.2% | 0.32% | $6,323,489,463 |
| VANGUARD GROUP INC | 10% | 13,553,932 | -0.08% | 0.08% | $5,389,721,059 |
| BlackRock, Inc. | 7.8% | 10,400,874 | +5% | 0.07% | $4,135,907,609 |
| Capital Research Global Investors | 5.1% | 6,779,708 | -6.1% | 0.5% | $2,695,945,984 |
| JPMORGAN CHASE & CO | 3.6% | 4,719,999 | +3.9% | 0.13% | $1,876,908,009 |
| STATE STREET CORP | 2.4% | 3,228,956 | +4.8% | 0.04% | $1,283,994,353 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,650,722 | +6.1% | 0.07% | $1,056,883,596 |
| BAILLIE GIFFORD & CO | 2% | 2,600,979 | -6.8% | 0.86% | $1,034,279,300 |
| NORGES BANK | 1.7% | 2,252,775 | 0.1% | $895,815,979 | |
| Invesco Ltd. | 1.6% | 2,165,840 | +46% | 0.13% | $861,246,230 |
| Dodge & Cox | 1.5% | 1,964,415 | -15% | 0.42% | $781,149,625 |
| T. Rowe Price Investment Management, Inc. | 1.3% | 1,753,640 | -19% | 0.44% | $697,335,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.3% | 1,702,831 | -5.4% | 0.07% | $677,132,000 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.2% | 1,628,931 | -11% | 0.11% | $647,744,413 |
| Orbis Allan Gray Ltd | 1.2% | 1,618,219 | -17% | 2.7% | $643,484,786 |
| AMERICAN CENTURY COMPANIES INC | 1.1% | 1,485,161 | -9.5% | 0.3% | $590,576,553 |
| TWO SIGMA ADVISERS, LP | 0.85% | 1,132,560 | +27% | 0.88% | $450,362,484 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.85% | 1,127,162 | -17% | 0.26% | $448,215,969 |
| MORGAN STANLEY | 0.73% | 970,157 | +34% | 0.02% | $385,784,277 |
| Legal & General Group Plc | 0.72% | 961,496 | +8.3% | 0.08% | $382,338,888 |
| AQR CAPITAL MANAGEMENT LLC | 0.69% | 919,959 | +24% | 0.19% | $365,821,629 |
| NORTHERN TRUST CORP | 0.65% | 857,742 | +3% | 0.04% | $341,081,107 |
| UBS Group AG | 0.62% | 825,840 | +69% | 0.07% | $328,395,275 |
| FRANKLIN RESOURCES INC | 0.59% | 787,623 | +10% | 0.08% | $313,198,267 |
Institutional Holders of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,588,240 | $1,185,680,288 | -$81,352,553 | $330.87 | 237 |
| 2025 Q4 | 129,412,755 | $51,476,964,087 | -$544,089,414 | $397.65 | 839 |
| 2025 Q3 | 129,757,754 | $59,159,078,884 | -$749,369,667 | $456.00 | 814 |
| 2025 Q2 | 132,062,946 | $43,060,444,035 | +$1,728,282,756 | $326.09 | 645 |
| 2025 Q1 | 126,881,187 | $34,233,011,857 | -$90,968,751 | $270.02 | 615 |
| 2024 Q4 | 127,632,870 | $30,037,175,866 | -$216,265,374 | $235.31 | 587 |
| 2024 Q3 | 123,754,217 | $34,035,461,284 | +$1,116,635,795 | $275.03 | 559 |
| 2024 Q2 | 119,818,858 | $29,121,298,158 | +$1,425,600,934 | $243.00 | 514 |
| 2024 Q1 | 114,506,382 | $17,112,788,490 | -$462,345,987 | $149.45 | 488 |
| 2023 Q4 | 117,037,909 | $22,406,153,370 | -$144,088,009 | $191.41 | 491 |
| 2023 Q3 | 117,774,911 | $20,850,702,200 | -$144,549,642 | $177.10 | 445 |
| 2023 Q2 | 118,559,398 | $22,525,153,339 | -$212,624,410 | $189.94 | 469 |
| 2023 Q1 | 119,657,504 | $23,956,079,414 | +$6,809,245 | $200.32 | 469 |
| 2022 Q4 | 119,654,959 | $28,425,215,078 | -$3,086,850,614 | $237.65 | 477 |
| 2022 Q3 | 133,393,008 | $26,709,327,641 | +$3,401,526,639 | $200.16 | 479 |
| 2022 Q2 | 113,477,846 | $16,543,858,767 | -$67,066,647 | $145.85 | 405 |
| 2022 Q1 | 113,908,234 | $18,598,579,814 | +$320,228,126 | $163.29 | 417 |
| 2021 Q4 | 112,006,374 | $18,989,908,067 | +$63,928,357 | $169.58 | 420 |
| 2021 Q3 | 111,604,687 | $21,068,206,424 | -$147,043,437 | $188.81 | 395 |
| 2021 Q2 | 112,239,402 | $19,027,485,774 | +$501,915,844 | $169.52 | 390 |
| 2021 Q1 | 109,361,699 | $15,431,272,628 | +$204,818,578 | $141.19 | 381 |
| 2020 Q4 | 107,900,409 | $14,018,800,907 | -$114,208,967 | $129.97 | 353 |
| 2020 Q3 | 108,499,178 | $15,789,451,789 | -$460,283,345 | $145.60 | 347 |
| 2020 Q2 | 111,562,100 | $16,522,566,788 | +$489,977,680 | $148.11 | 363 |
| 2020 Q1 | 108,370,173 | $11,796,531,647 | +$294,735,312 | $108.85 | 317 |
| 2019 Q4 | 105,328,965 | $12,129,387,603 | -$233,499,979 | $115.17 | 306 |
| 2019 Q3 | 108,059,417 | $8,689,910,646 | +$177,605,607 | $80.42 | 276 |
| 2019 Q2 | 106,070,864 | $7,694,654,472 | +$800,559,176 | $72.56 | 283 |
| 2019 Q1 | 96,763,330 | $9,041,659,322 | +$427,442,108 | $93.45 | 279 |
| 2018 Q4 | 92,434,388 | $6,736,307,943 | +$108,054,744 | $72.91 | 274 |
| 2018 Q3 | 90,577,162 | $7,927,334,207 | -$105,883,718 | $87.52 | 297 |
| 2018 Q2 | 91,541,386 | $9,015,538,809 | -$37,011,096 | $98.49 | 303 |
| 2018 Q1 | 91,623,594 | $10,912,571,096 | -$75,880,031 | $119.10 | 285 |
| 2017 Q4 | 92,127,969 | $11,704,641,437 | +$613,133,919 | $127.05 | 275 |
| 2017 Q3 | 87,490,797 | $10,279,386,005 | +$76,555,680 | $117.49 | 228 |
| 2017 Q2 | 87,236,413 | $6,951,381,175 | +$478,024,217 | $79.76 | 221 |
| 2017 Q1 | 82,296,913 | $4,218,075,181 | +$357,641,470 | $51.25 | 191 |
| 2016 Q4 | 79,901,866 | $2,991,766,834 | -$16,232,332 | $37.44 | 203 |
| 2016 Q3 | 77,521,060 | $5,253,109,562 | +$213,492,546 | $67.78 | 250 |
| 2016 Q2 | 74,050,576 | $4,109,046,677 | +$155,696,020 | $55.49 | 240 |
| 2016 Q1 | 70,923,645 | $4,451,021,161 | +$295,037,172 | $62.77 | 248 |
| 2015 Q4 | 66,039,006 | $6,216,981,299 | +$73,218,963 | $94.14 | 258 |
| 2015 Q3 | 65,414,849 | $5,256,534,541 | -$57,051,793 | $80.36 | 254 |
| 2015 Q2 | 65,565,499 | $7,859,319,459 | +$143,389,344 | $119.87 | 274 |
| 2015 Q1 | 64,472,950 | $6,731,323,619 | +$672,355,194 | $104.42 | 236 |
| 2014 Q4 | 57,984,886 | $5,624,460,197 | -$127,912,074 | $97.00 | 214 |
| 2014 Q3 | 58,977,372 | $4,606,139,951 | +$102,404,978 | $78.10 | 184 |
| 2014 Q2 | 57,779,618 | $3,648,879,764 | +$120,117,247 | $63.17 | 190 |
| 2014 Q1 | 55,704,223 | $3,739,161,613 | +$8,742,143 | $67.14 | 193 |